Kudriaeva A, Butenko I, Saratov G, Ri M, Mokrushina Y, Bondarev A
iScience. 2025; 28(3):111873.
PMID: 40060909
PMC: 11889684.
DOI: 10.1016/j.isci.2025.111873.
Gattinger P, Kozlovskaya L, Lunin A, Gancharova O, Sirazova D, Apolokhov V
Front Immunol. 2025; 16:1452814.
PMID: 39935478
PMC: 11811753.
DOI: 10.3389/fimmu.2025.1452814.
Wagner A, Garner-Spitzer E, Auer C, Gattinger P, Zwazl I, Platzer R
Vaccines (Basel). 2024; 12(5).
PMID: 38793769
PMC: 11125692.
DOI: 10.3390/vaccines12050518.
Sehgal A, Safran J, Kratzer B, Gattinger P, Stieger R, Musiejovsky L
Vaccines (Basel). 2024; 12(4).
PMID: 38675759
PMC: 11053794.
DOI: 10.3390/vaccines12040377.
Gattinger P, Kratzer B, Sehgal A, Ohradanova-Repic A, Gebetsberger L, Tajti G
Vaccines (Basel). 2024; 12(3).
PMID: 38543863
PMC: 10975884.
DOI: 10.3390/vaccines12030229.
LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
de Moor W, Williamson A, Schafer G, Douglass N, Gers S, Sutherland A
Viruses. 2023; 15(7).
PMID: 37515096
PMC: 10383203.
DOI: 10.3390/v15071409.
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell.
Rabdano S, Ruzanova E, Pletyukhina I, Saveliev N, Kryshen K, Katelnikova A
Vaccines (Basel). 2023; 11(4).
PMID: 37112786
PMC: 10141225.
DOI: 10.3390/vaccines11040874.
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies.
Gattinger P, Ohradanova-Repic A, Valenta R
Int J Mol Sci. 2023; 24(6).
PMID: 36982424
PMC: 10048970.
DOI: 10.3390/ijms24065352.
Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
Byazrova M, Gattinger P, Astakhova E, Hofer G, Khaitov M, Filatov A
Int J Mol Sci. 2023; 24(6).
PMID: 36982183
PMC: 10049224.
DOI: 10.3390/ijms24065104.
Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants.
He C, Chen L, Yang J, Chen Z, Lei H, Hong W
Mol Biomed. 2023; 4(1):9.
PMID: 36894743
PMC: 9998262.
DOI: 10.1186/s43556-023-00121-7.
Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen.
Jager M, Dichtl S, Bellmann-Weiler R, Reindl M, Lass-Florl C, Wilflingseder D
J Infect Dis. 2022; 227(4):528-532.
PMID: 36315869
PMC: 9927074.
DOI: 10.1093/infdis/jiac432.
Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19.
Blanas A, Karsjens H, de Ligt A, Huijbers E, van Loon K, Denisov S
iScience. 2022; 25(8):104719.
PMID: 35813877
PMC: 9252865.
DOI: 10.1016/j.isci.2022.104719.
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.
Mair M, Mitterer M, Gattinger P, Berger J, Trutschnig W, Bathke A
Cancer Cell. 2022; 40(5):444-446.
PMID: 35429443
PMC: 9001251.
DOI: 10.1016/j.ccell.2022.04.003.
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L
Allergy. 2022; 77(8):2431-2445.
PMID: 35357709
PMC: 9111473.
DOI: 10.1111/all.15305.
Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma.
Kratzer B, Trapin D, Gattinger P, Oberhofer T, Sehgal A, Waidhofer-Sollner P
Vaccines (Basel). 2022; 10(3).
PMID: 35335006
PMC: 8949333.
DOI: 10.3390/vaccines10030374.
